Somatix, Bristol-Myers Squibb deal

Bristol-Myers will make a second $10 million investment in SOMA, after the gene therapy company received FDA clearance for a Phase III protocol for its GVAX cancer vaccine. The investment is expected on April 30. The number of shares purchased will be based on the average closing price of SOMA common for the five consecutive days ending two business days prior to the closing. ...